Key Takeaways
- All risks materialised at once: US tariffs, India GST-led destocking, elevated fatty alcohol prices and reformulation hit simultaneously, making this a rare quarter where every envisaged risk played out, with effects continuing into Q3.
- India volumes flat despite Tier 1 reformulation loss: GST rate cuts on FMCG products triggered inventory adjustments by large players, while high feedstock prices accelerated reformulation away from surfactants in the Performance segment. Non-Tier 1 customer volume growth compensated, keeping India flat YoY and QoQ.
- Egypt competition and AMET reformulation compound the pressure: AMET declined as Tier 1 share eroded in Egypt against aggressive backward-integrated local players, while elevated fatty alcohol prices also prompted reformulation in those markets. Türkiye delivered strong double-digit growth, partially offsetting the Egypt weakness.
- US tariffs are delaying, not killing, the project pipeline: Customers are reviewing supply chains and going slow on commercialising projects, wary of inflation's impact on demand. The company is re-jigging supplies to its Egypt facility and evaluating capacity builds there if tariffs prove sustainable.
- What to watch next quarter: Whether the first signs of India recovery seen in November translate into a Q4 uptick, the pace of alternate surfactant commercialisation, and any softening in palm kernel oil prices that could begin to unwind reformulation.
The Quarter's Triple Hit
- US tariffs: The 50% tariff on exports from India adversely impacted existing businesses where applicable and continues to affect projects in the pipeline. The company shipped material ahead of the tariff imposition to minimise the short-term hit and is preparing to service demand from its Egypt plant.
- India GST disruption: GST rate reduction on FMCG products prompted large players to adjust inventories, leading to softer uptake and subdued volumes. Management reads customer calls and investor presentations: all big customers cited GST impact on their results, with some guiding that pain would continue into October.
- Fatty alcohol prices and reformulation: Lower-than-expected palm kernel oil production kept feedstock prices elevated, a condition expected to persist into October and November. This accelerated reformulation in the Performance segment, reducing active ingredient content (e.g., from 10% to 9% active) and hitting Tier 1 category volumes in both India and AMET markets.
- Freight and supply side: Freight costs eased compared to previous quarters, but shipment delays continued due to port congestion and blank sailings. Raw material availability showed signs of improvement, though pricing pressure remained, particularly in oleochemicals.
Natarajan: "This is one of the rare quarters where perhaps all the risks that we had envisaged have played out and continue to do so even into Q3."
India: Reformulation, Recovery and the Tier Mix Shift
- Reformulation is not structural: Management stated this is the fifth such episode in 32 years. Customers are clear they do not want to do this structurally because putting a petrochemical ingredient in personal care formulation is undesirable. It is driven by an unhealthy demand environment and inflationary impact, with reformulations gaining pace from August.
- Volume loss partially recouped: Aggressive marketing strategies in Tier 2 and Tier 3 have somewhat recouped the volume lost in Tier 1, though complete volume has not been recovered. The company gained a larger share of business with non-Tier 1 accounts, which largely mitigates but does not fully offset the Tier 1 reformulation impact.
- Recovery timeline: First signs of recovery were seen in November. Based on discussions with large customers, management expects gradual but steady recovery once adjustments are done, with steady improvement in India numbers starting from Q4 FY26. Q3 will be a problem due to missed festive demand and an extended, more severe winter.
- Alternate surfactants: The company has undertaken required capacity readjustments and developed alternate surfactants commercial capability. Requisite approvals are expected in Q3, with business commercialising from Q4 FY26.
Natarajan: "I don't see this as anything structural because in my last 32 years in this business, this is probably the fifth time that we are going through the situation, elevated fatty alcohol prices, people looking at reformulation."
AMET and Rest of World: Diverging Paths
- AMET decline drivers: Egypt saw continued market share erosion in Tier 1 due to intensified competition from aggressive local players who are backward integrated. High fatty alcohol prices also prompted reformulation in AMET markets, reducing active ingredient content. Management believes AMET has bottomed out in terms of demand not going further down.
- Türkiye offset: Türkiye delivered strong double-digit volume growth, partially offsetting the slower-than-expected recovery in Egypt. However, the region overall remains muted, with most economies ravaged by inflation and geopolitical tensions.
- Rest of World strength: Latin America and Asia Pacific maintained a strong growth trajectory with double-digit YoY gains, fuelled by robust demand across both Performance and Specialty Products. North America saw a decline primarily due to reciprocal tariffs impacting demand and margins in the Specialty Care segment.
- Super Specialty resilience: The Super Specialty prestige segment, led by TRI-K, continued to perform well, partially offsetting margin pressure in North America.
- Egypt entity health: Galaxy Chemicals Egypt as an entity is doing very well in terms of its product portfolio; management called it a great move for the company.
US Tariffs: Impact, Mitigation and Customer Behaviour
- Project delays, not cancellations: Certain businesses have been put on hold and certain projects in the pipeline expected to fructify this year have been delayed. Customers are reviewing their supply chains (what is coming from where, how to make it sustainable, short-term vs medium-term plans), and their ability to focus on currently building projects is impacted. They have not shelved them, but they need time.
- Industry-wide, not Galaxy-specific: One of the biggest players and customers in the US market has clearly talked about the US being a cost of concern and looking at China as a way to compensate. The impact is not specific to Galaxy; everyone has an impact because of the tariff. From India, the impact is much higher because the tariff is 50%, whereas even for feedstocks, local players have to bear a tariff: the delta between the tariff implications is what matters.
- Mitigation underway: The company is looking at how a good portion of the tariff impact, if it continues, can be managed through re-jigging supplies to the Egypt facility. It is also evaluating building certain capacities in Egypt if tariffs prove sustainable. Plans for US capacity expansion at TRI-K are being prepared on the drawing board, but clarity is needed on how sustainable tariffs will be and how demand will be impacted.
- Product specifics withheld: Management declined to discuss which product categories are affected by tariffs, citing competitive confidentiality as they work on solutions.
Natarajan: "When we talk to our customers they are not happy with this tariff coming in because you know that every customer would want to have a diversified vendor base and also more dependable vendors."
New Product Pipeline and Innovation
- Sun Care launches: At the recent in-cosmetics event in Bangkok (November first week), the company launched five products, all in the Sun Care range: the latest second-generation sunscreen molecules. It also launched a good range of products in the Beauty segment, focused on live-on-skin formulations. The Sun Care launch received a very fantastic response from all customers.
- Pipeline building: A very healthy pipeline of projects is being built across APAC, Europe and the US for these new molecules. Management expects to have a much better view on the Sun Care ingredients taking off in the next quarter.
- EPC contract: The project is progressing well and as per timeline. Revenue will be recognised based on certain basic minimum completion percentages; it is spread over more than a year. Management declined to give any number for year-end recognition.
Raw Material and Margin Dynamics
- Palm kernel oil prices: Underlying demand worldwide is not keeping pace (Europe, US), and the supply side has not been supportive in bringing prices down. There are some indications of palm kernel oil prices coming down in the last two weeks, but management says to wait and watch. As demand-side headwinds continue, the demand side will start bringing required corrections.
- Reformulation reversal mechanics: Reversals typically happen about 12 to 15 months after reformulation has occurred, once oleochemical prices start correcting and customers see the correction is going to sustain. This will be a function of palm kernel oil prices coming down.
- EBITDA per metric ton: The number was omitted from the press release and presentation. When asked, management provided it: ₹17,300 per metric ton, but did not address the reason for the omission.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India volume recovery | Steady improvement in India numbers, demand reactivation starting | From Q4 FY26 |
| Alternate surfactants commercialisation | Requisite approvals expected in Q3; business to commercialise | Q4 FY26 |
| Q3 performance | Q3 expected to end almost similar to Q2 | Q3 FY26 |
| Long-term volume growth target | 6% to 8% growth target unchanged | Long-term (no date) |
| Reformulation reversal | Typically 12–15 months after reformulation, contingent on palm kernel oil price correction | Function of feedstock prices |
| Egypt capacity expansion | Evaluating building certain capacities if tariffs prove sustainable | Conditional on tariff sustainability |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated volumes | Flat, YoY and QoQ |
| Performance Surfactants volumes | High-single-digit decline |
| Mass specialties volumes | Double-digit growth, driven by non-US geographies |
| H1 FY26 consolidated revenue | +2% YoY, driven by double-digit growth for Specialty Care products and flat Performance Surfactants |
| H1 FY26 EBITDA | ₹251 cr, -5% YoY from ₹265 cr in H1 FY25 |
| H1 FY26 EBITDA per metric ton | ~₹18,700 |
| Q2 FY26 EBITDA per metric ton | ₹17,300 |
| India volumes | Flat YoY and QoQ; single-digit impact from GST adjustments and reformulation recouped by non-Tier 1 gains |
| AMET volumes | High-single-digit decline YoY, modest single-digit decline QoQ; 30% lower from peak of 4-5 years ago |
| Türkiye volumes | Strong double-digit growth, QoQ and YoY |
| Latin America and Asia Pacific volumes | Double-digit YoY gains, across Performance and Specialty Products |
| US reciprocal tariffs full-year EBITDA impact | 3% to 5% of FY25 EBITDA |
| Reformulation volume impact in India | 3,000 to 4,000 tons of higher volume lost in the quarter |
| CWIP as of FY25 | ~₹260 cr, mostly in India with some in Egypt |